Replicated international studies have underscored the human and societal costs associated
with major depressive disorder. Despite the proven efficacy of monoamine-based …

This is the first systematic review of the safety of ketamine in the treatment of depression
after single and repeated doses. We searched MEDLINE, PubMed, PsycINFO, and …

Major depressive disorder (MDD) is severely disabling, and current treatments have limited
efficacy. The glutamate N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine was …

Ketamine, a drug introduced in the 1960s as an anesthetic agent and still used for that
purpose, has garnered marked interest over the past two decades as an emerging treatment …

Depression is disabling and highly prevalent. Intravenous (IV) ketamine displays rapid-onset
antidepressant properties, but little is known regarding which patients are most likely to …

This manuscript reviews the clinical evidence regarding single-dose intravenous (IV)
administration of the novel glutamatergic modulator racemic (R, S)-ketamine (hereafter …

Objectives To evaluate feasibility and effects of a sub‐anesthetic infusion dose of ketamine
versus midazolam on suicidal ideation in bipolar depression. Neurocognitive, blood and …

A subset of patients with depression have elevated levels of inflammatory cytokines, and
some studies demonstrate interaction between inflammatory factors and treatment outcome …

Replicated evidence has documented cognitive deficits in populations with treatment-
resistant depression (TRD). Approximately 40% of patients with MDD present with …

Impaired cognition is often overlooked in the clinical management of depression, despite its
association with poor psychosocial functioning and reduced clinical engagement. There is …